Progress in neuroprotection in Parkinson's disease.
Slowing or aborting the progress of neurodegeneration in Parkinson's disease (PD) remains the most important unmet need of this disorder. There are several recent developments in trial design and also in drugs under investigation for possible neuroprotective effect. Emphasis has been placed on clinical as opposed to imaging end-points and these include change in a clinical rating scale, e.g. United Parkinson's disease Rating Scale (UPDRS), or time to additional therapy. The introduction of the delayed-start, or wash-in, trial design adds an additional dimension to drug evaluation for neuroprotection. Compounds that have been recently tested in clinical trial include the monoamine oxidase-B inhibitor rasagiline, the anti-apoptotic agents TCH346 and CEP1347, and the promitochondrial agent creatine. The dopamine agonists have been evaluated for a neuroprotective effect using imaging end-points. Perhaps the most important and simplest concept for neuroprotection has been the theory that early dopaminergic support for the degenerating dopaminergic system per se provides significant long-term clinical benefit for PD patients.
Schapira
A H V
AH
University Department of Clinical Neurosciences, Institute of Neurology, University College London, London, UK. a.schapira@medsch.ucl.ac.uk
D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000639:trends; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control*
D000978:Antiparkinson Agents; D018696:Neuroprotective Agents